{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:19Z","timestamp":1793823979653,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage diseases caused by defective enzyme activity involved in the catalysis of glycosaminoglycans. Published data on adult patients with MPS remains scarce. Therefore, the present qualitative survey study was aimed at understanding knowledge of the disease, unmet needs, expectations, care, and overall medical management of adult\/adolescent patients with MPS I, II and VI and their caregivers in France.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 25 patients (MPS I, n<jats:sub>p<\/jats:sub>\u2009=\u200911; MPS II, n<jats:sub>p<\/jats:sub>\u2009=\u20099; MPS VI, n<jats:sub>p<\/jats:sub>\u2009=\u20095) were included and about 36 in-depth interviews (caregivers alone, n<jats:sub>c<\/jats:sub>\u2009=\u20098; patients-caregiver pair, n<jats:sub>c+p<\/jats:sub>\u2009=\u200922; patients alone, n<jats:sub>p<\/jats:sub>\u2009=\u20096) were conducted. Except one (aged 17\u00a0years), all patients were adults (median age: 29\u00a0years [17\u201350]) and diagnosed at median age of 4\u00a0years [0.4\u201330], with mainly mothers as caregivers (n<jats:sub>c<\/jats:sub>\u2009=\u200916\/19). Patients were classified into three groups: Group A, Patients not able to answer the survey question because of a severe cognitive impairment (n<jats:sub>p<\/jats:sub>\u2009=\u20098); Group B, Patients able to answer the survey question with low or no cognitive impairment and high motor disability (n<jats:sub>p<\/jats:sub>\u2009=\u200910); and Group C, Patients able to answer the survey question with low or no cognitive impairment and low motor disability (n<jats:sub>p<\/jats:sub>\u2009=\u20097). All groups were assessed for impact of disease on their daily lives based on a scale of 0\u201310. Caregivers in Group A were found to be most negatively affected by the disease, except for professional activity, which was most significantly impacted in Group B (4.7 vs. 5.4). The use of orthopaedic\/medical equipments, was more prevalent in Groups A and B, versus Group C. Pain management was one of the global unmet need expressed by all groups. Group A caregivers expected better support from childcare facilities, disability clinics, and smooth transition from paediatric care to adult medicine. Similarly, Group B caregivers expected better specialised schools, whereas Group C caregivers expected better psychological support and greater flexibility in weekly infusion schedules for their patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The survey concluded that more attention must be paid to the psychosocial status of patients and caregivers. The preference for reference centre for follow-up and treatment, hospitalizations and surgeries were evident. The most significant needs expressed by the patients and caregivers include better understanding of the disease, pain management, monitoring of complications, flexibility in enzyme replacement therapy, home infusions especially for attenuated patients, and improved transitional support from paediatric to adult medicine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02593-2","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:19:03Z","timestamp":1671815943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-2366","authenticated-orcid":false,"given":"Nathalie","family":"Guffon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Genevaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Le Peillet Feuillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Bausson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"issue":"1","key":"2593_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","volume":"16","author":"Y Puckett","year":"2021","unstructured":"Puckett Y, Mallorga-Hern\u00e1ndez A, Monta\u00f1o AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis. 2021;16(1):241.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2593_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/diagnostics11020273","volume":"11","author":"B \u00c7elik","year":"2021","unstructured":"\u00c7elik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of mucopolysaccharidoses update. Diagnostics (Basel). 2021;11(2):273.","journal-title":"Diagnostics (Basel)"},{"key":"2593_CR3","doi-asserted-by":"publisher","first-page":"2408402","DOI":"10.1155\/2020\/2408402","volume":"2020","author":"H Nan","year":"2020","unstructured":"Nan H, Park C, Maeng S. Mucopolysaccharidoses I and II: brief review of therapeutic options and supportive\/palliative therapies. Biomed Res Int. 2020;2020:2408402.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2593_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ajmg.a.33779","volume":"155","author":"B H\u00e9ron","year":"2011","unstructured":"H\u00e9ron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A. 2011;155(1):58\u201368.","journal-title":"Am J Med Genet A"},{"issue":"15","key":"2593_CR5","doi-asserted-by":"publisher","first-page":"7888","DOI":"10.3390\/ijms22157888","volume":"22","author":"CS Hampe","year":"2021","unstructured":"Hampe CS, Yund BD, Orchard PJ, Lund TC, Wesley J, McIvor RS. Differences in MPS I and MPS II disease manifestations. Int J Mol Sci. 2021;22(15):7888.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2593_CR6","first-page":"89","volume":"3","author":"C Decker","year":"2010","unstructured":"Decker C, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3(2):89\u2013100.","journal-title":"J Pediatr Rehabil Med"},{"key":"2593_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejim.2016.05.017","volume":"34","author":"J Mitchell","year":"2016","unstructured":"Mitchell J, Berger KI, Borgo A, Braunlin EA, Burton BK, Ghotme KA, et al. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med. 2016;34:2\u201310.","journal-title":"Eur J Intern Med"},{"issue":"11","key":"2593_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"JB Eisengart","year":"2018","unstructured":"Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med. 2018;20(11):1423\u20139.","journal-title":"Genet Med"},{"issue":"1","key":"2593_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229\u201340.","journal-title":"Pediatrics"},{"issue":"1","key":"2593_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","volume":"96","author":"R Giugliani","year":"2009","unstructured":"Giugliani R, Rojas VM, Martins AM, Valadares ER, Clarke JT, G\u00f3es JE, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2009;96(1):13\u20139.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2593_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"2593_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171\u201380.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2593_CR13","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37-46.","journal-title":"Pediatrics"},{"issue":"Suppl 2","key":"2593_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.","journal-title":"Ital J Pediatr"},{"issue":"11","key":"2593_CR15","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1002\/ajmg.a.62460","volume":"185","author":"N Grant","year":"2021","unstructured":"Grant N, Von Handorf R, Karaa A, Skotko BG. The experiences and support needs of siblings of people with mucopolysaccharidosis. Am J Med Genet A. 2021;185(11):3418\u201326.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2593_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41687-019-0140-3","volume":"3","author":"M Harrington","year":"2019","unstructured":"Harrington M, Hareendran A, Skalicky A, Wilson H, Clark M, Mikl J. Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the caregiver impact questionnaire. J Patient Rep Outcomes. 2019;3(1):44.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"2593_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13023-016-0521-0","volume":"11","author":"S Somanadhan","year":"2016","unstructured":"Somanadhan S, Larkin PJ. Parents\u2019 experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS). Orphanet J Rare Dis. 2016;11(1):138.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2593_CR18","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1093\/rheumatology\/keab154","volume":"60","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Bendstrup E, Dimitroulas T, Hesselstrand R, Morais A, Peltomaa R, et al. Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology (Oxford). 2021;60(12):5601\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2593_CR19","first-page":"436","volume":"67","author":"Z Austin","year":"2014","unstructured":"Austin Z, Sutton J. Qualitative research: getting started. Can J Hosp Pharm. 2014;67(6):436\u201340.","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"2593_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1054773818780102","volume":"29","author":"J Granero-Molina","year":"2020","unstructured":"Granero-Molina J, S\u00e1nchez-Hern\u00e1ndez F, Fern\u00e1ndez-Sola C, Jim\u00e9nez-Lasserrotte MDM, Antequera-Raynal LH, Hern\u00e1ndez-Padilla JM. The diagnosis of hereditary angioedema: family caregivers\u2019 experiences. Clin Nurs Res. 2020;29(2):117\u201326.","journal-title":"Clin Nurs Res"},{"key":"2593_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","volume":"10","author":"N Guffon","year":"2015","unstructured":"Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2593_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","volume":"11","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, et al. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet J Rare Dis. 2016;11(1):119.","journal-title":"Orphanet J Rare Dis"},{"key":"2593_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/8904_2018_119","volume":"44","author":"T Conijn","year":"2019","unstructured":"Conijn T, Nijmeijer SCM, van Oers HA, Wijburg FA, Haverman L. Psychosocial functioning in parents of MPS III patients. JIMD Rep. 2019;44:33\u201341.","journal-title":"JIMD Rep"},{"issue":"3","key":"2593_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/1367493513485825","volume":"18","author":"C Malcolm","year":"2014","unstructured":"Malcolm C, Gibson F, Adams S, Anderson G, Forbat L. A relational understanding of sibling experiences of children with rare life-limiting conditions: findings from a qualitative study. J Child Health Care. 2014;18(3):230\u201340.","journal-title":"J Child Health Care"},{"issue":"4","key":"2593_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","volume":"33","author":"R Giugliani","year":"2010","unstructured":"Giugliani R, Federhen A, Rojas MV, Vieira T, Artigal\u00e1s O, Pinto LL, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589\u2013604.","journal-title":"Genet Mol Biol"},{"key":"2593_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-1172-5-5","volume":"5","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2593_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13023-021-02074-y","volume":"16","author":"P Quijada-Fraile","year":"2021","unstructured":"Quijada-Fraile P, Arranz Canales E, Mart\u00edn-Hern\u00e1ndez E, Ballesta-Mart\u00ednez MJ, Guill\u00e9n-Navarro E, Pintos-Morell G, et al. Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience. Orphanet J Rare Dis. 2021;16(1):464.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2593_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.pedn.2011.07.003","volume":"27","author":"HM Nicholl","year":"2012","unstructured":"Nicholl HM, Begley CM. Explicating caregiving by mothers of children with complex needs in ireland: a phenomenological study. J Pediatr Nurs. 2012;27(6):642\u201351.","journal-title":"J Pediatr Nurs"},{"issue":"23","key":"2593_CR29","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/ijerph17238975","volume":"17","author":"J Boettcher","year":"2020","unstructured":"Boettcher J, Denecke J, Barkmann C, Wiegand-Grefe S. Quality of life and mental health in mothers and fathers caring for children and adolescents with rare diseases requiring long-term mechanical ventilation. Int J Environ Res Public Health. 2020;17(23):8975.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"2593_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10545-014-9737-0","volume":"38","author":"MM Brands","year":"2015","unstructured":"Brands MM, G\u00fcng\u00f6r D, van den Hout JM, Karstens FP, Oussoren E, Plug I, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis results of a cross-sectional national survey. J Inherit Metab Dis. 2015;38(2):323\u201331.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2593_CR31","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/j.1651-2227.2011.02522.x","volume":"101","author":"J Marucha","year":"2012","unstructured":"Marucha J, Jurecka A, Syczewska M, R\u00f3\u017cd\u017cy\u0144ska-\u015awi\u0105tkowska A, Tylki-Szyma\u0144ska A. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr. 2012;101(4):e183\u20138.","journal-title":"Acta Paediatr"},{"key":"2593_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/8904_2014_396","volume":"20","author":"N Ali","year":"2015","unstructured":"Ali N, Cagle S. Psychological health in adults with morquio syndrome. JIMD Rep. 2015;20:87\u201393.","journal-title":"JIMD Rep"},{"issue":"1","key":"2593_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-022-02232-w","volume":"17","author":"D Genevaz","year":"2022","unstructured":"Genevaz D, Arnoux A, Marcel C, Brassier A, Pichard S, Feillet F, et al. Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey. Orphanet J Rare Dis. 2022;17(1):68.","journal-title":"Orphanet J Rare Dis"},{"key":"2593_CR34","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.1016\/j.ymgmr.2019.100508","volume":"21","author":"C Lampe","year":"2019","unstructured":"Lampe C, McNelly B, Gevorkian AK, Hendriksz CJ, Lobzhanidze TV, P\u00e9rez-L\u00f3pez J, et al. Transition of patients with mucopolysaccharidosis from paediatric to adult care. Mol Genet Metab Rep. 2019;21:100508.","journal-title":"Mol Genet Metab Rep"},{"key":"2593_CR35","doi-asserted-by":"publisher","first-page":"652358","DOI":"10.3389\/fmed.2021.652358","volume":"8","author":"KM Stepien","year":"2021","unstructured":"Stepien KM, Kie\u0107-Wilk B, Lampe C, Tangeraas T, Cefalo G, Belmatoug N, et al. Challenges in transition from childhood to adulthood care in rare metabolic diseases: results from the first multi-center european survey. Front Med (Lausanne). 2021;8:652358.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2593_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):118.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2593_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40271-020-00482-z","volume":"14","author":"AC Jimenez-Moreno","year":"2021","unstructured":"Jimenez-Moreno AC, van Overbeeke E, Pinto CA, Smith I, Sharpe J, Ormrod J, et al. Patient preferences in rare diseases: a qualitative study in neuromuscular disorders to inform a quantitative preference study. Patient. 2021;14(5):601\u201312.","journal-title":"Patient"},{"issue":"1","key":"2593_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13104-018-3157-4","volume":"11","author":"MR Oliveira","year":"2018","unstructured":"Oliveira MR, Schwartz I, Costa LS, Maia H, Ribeiro M, Guerreiro LB, et al. Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique. BMC Res Notes. 2018;11(1):28.","journal-title":"BMC Res Notes"},{"issue":"2","key":"2593_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1471-6712.2004.00258.x","volume":"18","author":"A Lindseth","year":"2004","unstructured":"Lindseth A, Norberg A. A phenomenological hermeneutical method for researching lived experience. Scand J Caring Sci. 2004;18(2):145\u201353.","journal-title":"Scand J Caring Sci"},{"key":"2593_CR40","volume-title":"Qualitative inquiry and research design: choosing among five approaches","author":"JW Creswell","year":"2013","unstructured":"Creswell JW. Qualitative inquiry and research design: choosing among five approaches. Los Angeles: SAGE Publications; 2013."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02593-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:20:14Z","timestamp":1671816014000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2593"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02593-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent forms will be made available on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eliane Le Peillet Feuillet is a Sanofi employee and may hold shares and\/or stock options in the company. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}